Writer: Lois

Photo: Dado Ruvic / Reuters

Coroners have linked the deaths of two British residents with blood-clotting disorders related to their injections with British drugmaker AstraZeneca’s COVID-19 vaccine.

One of the residents, Kim Lockwood, was a 34-year-old mother from South Yorkshire. She died in March 2021 from bleeding in the brain nine days after her AstraZeneca vaccination.

Ms Lockwood, who reported an excruciating headache eight days after her vaccination, was pronounced dead 17 hours after hospitalisation.

South Yorkshire coroner Nicola Mundy, who examined Ms Lockwood’s body, called the case “extremely unlucky”. She recorded the cause of death as vaccine-induced thrombotic thrombocytopenia (VITT), which a medical study describes as “a novel entity that emerged in March 2021 following reports of unusual thrombosis after ChAdOx1 nCov-19, (AstraZeneca) vaccination.”

An investigation into the death of Tom Dudley, a 31-year-old father of two from Sheffield County who passed away on May 14, 2021, revealed that he died from a vaccine-induced brain haemorrhage.

Mr Dudley received his AstraZeneca COVID-19 vaccine on April 27, 2021.

On May 7, 2021, after the deaths of Ms Lockwood and Mr Dudley, Britain’s National Health Service released a new set of guidelines warning that healthy individuals under 40 should not receive the vaccine because of blood-clot risks.

According to assistant coroner Tanyka Rawden, before Mr Dudley’s death, the blood-clotting complication was not known and linked to the AstraZeneca vaccine.

“It seems to me that the guidelines have been changed. They were changed very, very quickly after Tom had his vaccination,” stated the coroner.

British government statistics reveal that there have been 437 reported cases and 78 deaths from blood-clotting issues out of around 24.9 million first doses and 24.2 million second doses of the AstraZeneca vaccine within the population.

Many European nations, including France, Germany, Italy, and Spain, have suspended the distribution of the AstraZeneca vaccine since April 2021, after health experts discovered potentially fatal blood clots in some vaccinated individuals.

In the leading medical journal The BMJ, researchers published a study on May 5, 2021, which confirmed blood clotting in AstraZeneca vaccine recipients, with blood clot risks developing even after just one dose of the vaccine.

“[We observed] an increased rate of venous thromboembolic events, corresponding to 11 excess venous thromboembolic events per 100,000 vaccinations and including a clearly increased rate of cerebral venous thrombosis with [seven] observed events versus 0.3 expected events among the 282,572 vaccine recipients,” wrote the study authors.

AstraZeneca has announced that it will not submit its vaccine for approval in the US if the regulatory process is too long. Instead, it will focus on selling the vaccine in other countries.

The Johnson & Johnson COVID-19 vaccine approved for emergency use in the United States uses the same adenovirus technology as the United Kingdom’s AstraZeneca vaccine.

The US Food and Drug Administration (FDA) included a contraindication, or warning, in its fact sheets for Emergency Use Authorization of the J&J vaccine for adults with a history of thrombosis with thrombocytopenia syndrome (TTS).

According to the FDA, the highest rate of TTS was reported in women aged 30 to 49, although victims included both men and women across a wide range of ages. Around 15 per cent of the total TTS cases were fatal.

The US Vaccine Adverse Event Reporting System (VAERS) revealed 2,607 reports of blood-clotting disorders following the J&J vaccine between December 14, 2020, and March 4, 2022.

On December 16, 2021, the US Centers for Disease Control and Prevention (CDC) recommended that individuals 18 and over receive COVID-19 mRNA vaccines from Pfizer-BioNTech or Moderna mRNA vaccines instead of the J&J vaccine.

Pfizer and Moderna’s experimental COVID-19 mRNA vaccines have also been linked to blood clots. However, despite reports and studies proving the risk of these conditions with COVID-19 mRNA vaccines, the FDA and CDC have not included warnings of blood-clotting disorders with the Pfizer and Moderna vaccines.

An Oxford University study published in April 2021 showed the number of vaccine recipients who developed cerebral venous sinus thrombosis (CVST) were 4 in 1 million people for the Pfizer or Moderna vaccine, while the number was 5 in 1 million for the AstraZeneca vaccine.

The study did not include the J&J vaccine as it is not approved for use in the European Union (EU).

Upload Layout: V ontheway (V 在途中)